Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Rituximab
 More »

  • Lilly Phase III Candidate Meets Primary Endpoint of NSCLC Overall...
    failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based chemotherapy. ...
    8-13-2013
  • Membrane Protein Monoclonal Antibodies
    ... Similarly, most existing CD20 mAbs fall into two classes (rituximab-like and ofatumumab-like). The CD20 mAbs isolated from DNA-immunized mice exhibit nine known and novel ...
    8-1-2013
  • Genentech Trumpets Phase III Results for CLL Candidate
    candidate plus chlorambucil resulted in "significantly" longer progression-free survival (PFS) compared with its previous-generation version, Rituxan (rituximab) plus chlorambucil. ...
    7-24-2013
  • Leukemia & Lymphoma Society Injects $6M into Valor's NHL Candidate
    clinically validated anti-cancer drugs, rituximab and interferon alpha," LLS said in a ... "IGN002 has demonstrated dramatic efficacy in rituximab-resistant preclinical models. ...
    5-22-2013
  • Phase III Failure for Pfizer NHL Drug
    once-a-month schedule in combination with rituximab and compared with an active comparator arm (investigator's choice of bendamustine plus rituximab or gemcitabine plus rituximab). ...
    5-21-2013
  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    ... idelalisib in combination with rituximab for older patients with treatment-naïve CLL. Gilead said patients treated with the idelalisib-rituximab combination achieve a complete ...
    5-16-2013
  • Lilly Halts Development of Lymphoma Drug After Phase III Failure
    Enzastaurin failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of DLBCL relapse following rituximab-based ...
    5-10-2013
  • Biosimilars: 10 Drugs to Watch
    ... announcing plans August 2011 to collaborate on biosimilars for trastuzumab and rituximab. ... and 2018 in U.S. Rituxan / MabThera (rituximab) Drug developers: Amgen: Biosimilar in ...
    4-22-2013
  • Pharmacyclics Achieves Another $50M Milestone
    trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL enrolled its fifth patient in ...
    4-11-2013
  • Electronics Giants Set Sights on Biotech
    ... Last October, the company halted development of a biosimilar version of the Roche/Biogen Idec lymphoma and rheumatoid arthritis drug Rituxan (rituximab)-just six months after ...
    4-1-2013
  • Biosimilars: Not So Far So Fast
    (through its joint venture with Lonza) is evaluating the path forward for rituximab." ... competition, suggesting biosimilar rituximab could enter the market in 2016. This ...
    3-15-2013
  • Top 20 Best-Selling Drugs of 2012
    ... 22.6% at CER from $1.413 billion (€1.054 billion) in 4Q 2011 at CER 5 #5. Rituxan (rituximab, MabThera) Drug maker: Roche Indication(s): Non-Hodgkin's lymphoma, chronic ...
    3-1-2013
  • Optimizing the Quality and Accuracy of Biopharmaceutical Analysis...
    Kimzey will discuss assessing variability of an innovator glycan profile for development of a biosimilar. He will present rituximab and bevacizumab glycan profile data generated ...
    2-19-2013
  • Bittersweet News at Biogen Idec
    Avonex (interferon beta-1a) for relapsing forms of MS. The drug generated $753.2 million in Q4, up 7% from $703.2 million. Rituxan (rituximab) revenue from an unconsolidated joint ...
    1-28-2013
  • Where Downstream Operations Are Headed
    it is a very competitive marketplace, and Teva and Lonza have already halted their rituximab biosimilar development, so looking at areas such as cost reductions in manufacturing ...
    1-1-2013
  • More »

    Journal Articles

  • Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma...
    Christos Emmanouilides, Ali R. Jazirehi, Benjamin Bonavida
    Cancer Biotherapy and Radiopharmaceuticals
    Rituximab-Mediated Sensitization of B-Non-Hodgkin's Lymphoma (NHL) to Cytotoxicity Induced ... Currently, rituximab (anti-CD20) has been approved for treatment of indolent NHL, with ...
  • Rituximab Treatment for Thrombotic Thrombocytopenic Purpura Associated...
    Michael W. Evans, Leroy B. Vaughan, Victoria S. Giffi, Ann B. Zimrin, John R. Hess
    AIDS Patient Care and STDs
    Rituximab Treatment for Thrombotic Thrombocytopenic Purpura Associated with Human ... Patients were subsequently treated with 2-4 doses of weekly rituximab resulting in durable ...
  • Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning...
    Paul C. Kruger, Julian P. Cooney, J. Harvey Turner
    Cancer Biotherapy and Radiopharmaceuticals
    Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell ... We have introduced concomitant 131I-rituximab radioimmunotherapy (RIT) in an attempt to ...
  • Rituximab Plus Dose-Reduced Cyclophosphamide, Mitoxantrone, Vincristin...
    Constanze Jonak, Marlene Troch, Leonhard Müllauer, Bruno Niederle, Martha Hoffmann, Markus Raderer
    Thyroid
    Rituximab Plus Dose-Reduced Cyclophosphamide, Mitoxantrone, Vincristine, and Prednisolone ... We present the results of systemic treatment using rituximab (R) plus dose reduced ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll